China Botanic Pharmaceutical Completes Research on the Chromatographic Fingerprints for Its Siberian Ginseng Series Products

April 14, 2011

HARBIN, China, April 14, 2011 /PRNewswire-Asia-FirstCall/ — China Botanic Pharmaceutical Inc. (AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, today announced that the Company has successfully completed research of the chromatographic fingerprints for its Siberian Ginseng series products, utilizing a state-of-the-art analysis method which identifies the chemical characteristics of the designated medicine.

The fingerprint technology discerns the so-called forensic “fingerprint” of herbal medicine components using advanced techniques including chromatographic or spectral profiling. The profile can be used to identify different species, families, genera, and cultivars of medicinal herbs, permitting reliable authentication and quality control for herbal materials.

The data developed during the work, which was completed in collaboration with Harbin Pharmaceutical Group’s Traditional Chinese Medicine No. 2 Factory, will be used by the Company to continue to improve and strengthen the quality of its Siberian Ginseng offerings.

Chinese medicine has a long history and its safety and effectiveness has been verified. However, Chinese medicines are generally administered as compounds, and the active ingredients of the medicine can be extremely complex. Under current conditions, a single chemical analysis method is not suitable for analyzing Chinese medicines and chromatographic fingerprinting technology is a significant step forward. The approach gives a full picture of the traditional Chinese medicine and its ingredients. With the fingerprint established, more reliable and consistent quality control can be implemented. This opens the way for even greater acceptance of TCMs worldwide.

“It is a breakthrough innovation for us to study and establish fingerprints for our Siberian Ginseng series products,” said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. “Quality control is the key to the effectiveness of our depression remedies, which are relied on by people throughout China for their proven relief of neurological conditions. We have invested heavily in our production processes and this leap forward is another example of the dedication of the China Botanic team to producing the best quality herbal medicines available anywhere.”

For a general discussion of fingerprinting in Chinese medicine, see http://www.innovationmagazine.com/innovation/volumes/v6n2/coverstory2.shtml.


China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon managements beliefs, assumptions and expectations of the Companys future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from he expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Companys ability to manage expansion of its operations effectively, and other factors detailed in the Companys annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:                       CCG Investor Relations:
                                            Mr. Mark Collinson,
    China Botanic Pharmaceutical Inc.       Partner
                                            Phone: +1-310-954-1343
    Ms. Portia Tan, IR Contact              (Los Angeles)
    Tel: 86-451-8260-2162                   mark.collinson@ccgir.com
    Email: ir@renhuang.com                 Website: www.ccgirasia.com

                                            Mr. Crocker Coulson,
                                            Phone: +1-646-213-1915
                                            (New York)

SOURCE China Botanic Pharmaceutical Inc.

Source: newswire

comments powered by Disqus